share_log

Pono Capital Corp Combination Partner Benuvia Receives Approval From DEA To Manufacture Psychedelic Active Pharmaceutical Ingredients including Psilocybin, MDMA And DMT

Pono Capital Corp Combination Partner Benuvia Receives Approval From DEA To Manufacture Psychedelic Active Pharmaceutical Ingredients including Psilocybin, MDMA And DMT

博諾資本公司組合合夥人 Benuvia 獲得 DEA 的批准,製造包括裸蓋菇鹼,MDMA 和 DMT 在內的迷幻活性藥物成分
Benzinga Real-time News ·  2022/05/16 07:51
With this approval, Benuvia has begun focusing on four primary psychedelic ingredients: Psilocybin, N,N-Dimethyl-5-Methoxy-Tryptamine (5-MeO DMT), Dimethyltryptamine (DMT), and 3,4-Methylenedioxymethamphetamine, or MDMA Benuvia will manufacture psychedelic APIs in its 83,000 square foot manufacturing facility that is permitted by the US DEA for Schedule I to III Controlled Substances, and is FDA registered and a cGMP facility Benuvia is positioning itself to become a leading global supplier of psychedelic active pharmaceutical ingredients (APIs), complementing its established portfolio of cannabinoid APIs
獲得批准後,Benuvia開始專注於四種主要的迷幻成分:裸蓋菇素、N,N-二甲基-5-甲氧基色胺(5-MeO DMT)、二甲基色胺(DMT)和3,4-亞甲基二氧基甲基苯丙胺,或MDMA Benuvia將在其83,000平方米英尺的製造工廠生產迷幻原料藥,該工廠是美國DEA允許的附表I至III受控物質,並已在FDA註冊,是一家cGMP工廠 Benuvia正在將自己定位為迷幻活性藥物成分(API)的全球領先供應商,以補充其已建立的大麻類API產品組合
ROUND ROCK, Texas, May 16, 2022 /PRNewswire/ -- Benuvia, Inc., a drug developer and manufacturer of APIs focused on cannabinoids, with...
亞洲網得克薩斯州朗洛克2022年5月...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論